Home › Funds › Aufman Associates Inc › ABT

Aufman Associates Inc position in ABT

ABBOTT LABORATORIES · Health Care

Aufman Associates Inc reported holding 3,051 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$302K, representing 0.12% of its reported portfolio and ranking #47 among its reported holdings. Aufman Associates Inc has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.05K sh
Reported value held$301.53K
Portfolio Weight0.12%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Aufman Associates Inc's ABT position evolved

Aufman Associates Inc first disclosed a stake in ABT in Q3 2023 at 3,051 shares (US$295K). The position peaked in Q2 2025 at 3,051 shares, worth US$415K. Across 13 filings, Aufman Associates Inc held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,051 shares valued at US$302K.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.05K $295.49K New
Q4 2023 3.05K $335.82K Hold
Q1 2024 3.05K $346.78K Hold
Q2 2024 3.05K $317.03K Hold
Q3 2024 3.05K $347.85K Hold
Q4 2024 3.05K $345.10K Hold
Q1 2025 3.05K $404.71K Hold
Q2 2025 3.05K $414.97K Hold
Q3 2025 3.05K $408.65K Hold
Q4 2025 3.05K $382.26K Hold
Q1 2026 3.05K $313.25K Hold
Q2 2026 3.05K $276.85K Hold
Q3 2026 3.05K $301.53K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Aufman Associates Inc held ABT?

Aufman Associates Inc has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Aufman Associates Inc's current position in ABT?

As of Q3 2026, Aufman Associates Inc holds 3.05K shares of ABT (ABBOTT LABORATORIES), valued at $301.53K, representing 0.12% of its reported portfolio and ranking #47.

Has Aufman Associates Inc been buying or selling ABT?

In the latest 13F filing (Q3 2026), Aufman Associates Inc held unchanged its position in ABT. The position peaked in Q2 2025 at 3.05K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.